Navigation Links
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea

NEWTOWN, Pa.--(BUSINESS WIRE)--Apr 30, 2007 - CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that a new report in the May 2007 issue of the Journal of the American Academy of Dermatology evaluating two randomized phase III clinical trials, demonstrated the efficacy and safety of anti-inflammatory dose doxycycline (Oracea(R), 40-mg doxycycline, USP capsules) for the treatment of rosacea. This report has concluded these studies establish the first important body of evidence supporting the use of a systemic therapy for rosacea that is devoid of antibiotic activity.

The study further concludes that "the antibacterial effects of doxycycline or other antibiotics have not been shown to be of therapeutic importance in rosacea, therefore an effective and safe formulation of this drug that does not exhibit antibiotic selection pressure is clinically significant."

Lead clinical investigator in these clinical trials, James Q. Del Rosso. DO, Department of Dermatology, University of Nevada School of Medicine, states, "This discussion of the significance of these phase III studies is of utmost importance to the way in which rosacea patients are treated going forward. The option of an effective systemic treatment for rosacea that is devoid of antibiotic activity helps dermatologists reduce their use of antibiotics. Antibiotic use correlates with a rise in bacterial resistance, a problem of global concern." Anti-inflammatory dose doxycycline was proven to be safe in both studies. The frequency of adverse events was similar to those of patients taking placebo. Of significant note was the finding that in both studies vaginal candidiasis and photosensitivity were not observed in the patients treated with anti-inflammatory dose doxycycline.

Also noteworthy was the fact that once daily dosing, based on a review of several studies, appears to be the dosing regimen associated with the highest rate of pati
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting
6. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
7. King Pharmaceuticals Announces Plan to Report Positive Data from Phase III Clinical Trial Evaluating the Combination of Altace with Hydrochlorothiazide
8. Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:7/23/2014)... 23, 2014  Researchers from the North American Menopause ... elevates calcium levels too high, 1 putting women ... Women close to menopause are commonly told ... prevent diseases such as osteoporosis, to which they are ... determine how much calcium they typically get through their ...
(Date:7/23/2014)... 23, 2014  Mevesi Inc. would like to ... integration provides pharmacies with the ability to send ... patients. Mevesi,s solutions provide an ... to define target marketing campaigns. This coupled with ... within the Digital Marketing, Population Management, and Pharmacy ...
(Date:7/23/2014)... 2014 Global healthcare company GSK ... currency headwinds, increased price competition and supply disruptions to ... Witty points out that the company is very much ... to be confident about long-term prospects as well as ... CFO Simon Dingemans adds that the ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Mevesi Enhances Solutions with Variable Print Media Capabilities! 2
... , , Trial taking place ... Ky., July 24 Michael (Mike) Jones has become the world,s first ... infusion on July 17 marks the world,s first phase-one FDA-approved clinical trial ... is being conducted by a team of University of Louisville physicians at ...
... , WISCONSIN RAPIDS, Wis., July 23 ... Riverview became the first medical facility in the world to ... within Riverview Hospital, Wisconsin Rapids, the UW Cancer Center Riverview ... FDA-cleared Axxent(R) Electronic Brachytherapy System from Xoft, Inc. Electronic Brachytherapy, ...
Cached Medicine Technology:World's First Cardiac Adult Stem Cell Patient Receives Infusion 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
(Date:7/23/2014)... Celebrating a decade of philanthropy in ... the awarding of $1,070,000 in grants to 20 New ... of the Foundation’s 1,000th grant. , “The Horizon Foundation ... of supporting community-based organizations that are working to improve ... the Garden State,” said Robert A. Marino, Horizon Blue ...
(Date:7/23/2014)... study supports a growing body of research suggesting ... hormones in treating postmenopausal breast cancer, with fewer ... with standard anti-hormone therapies. The study will be ... journal Reproductive Biology and Endocrinology . , ... in women in the United States. Approximately 70% ...
(Date:7/23/2014)... Global Cardio Care, Inc., a management ... (EECP), is celebrating the 100th birthday of Albert ... health center. , Weber has been plagued with ... EECP therapy since 1999, he no longer suffers from ... Global Cardio Care, introduced the Sara Soulati Health ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The voice on the ... call that brought the news he was infected with the human ... a little bit and next thing you know I was on ... , Yet the message was hopeful when the recording ended less ... of you . . . because it is just God ...
(Date:7/23/2014)... -- For patients infected with both HIV and hepatitis ... viruses, a small study suggests. Researchers said doctors ... people with the two diseases. "The findings ... important role in the management of individuals with [hepatitis ... Sherman, a professor of medicine at the University of ...
Breaking Medicine News(10 mins):Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2
... finds children with sickle cell disease are more likely to ... if they live in households where people smoke.// ,Study ... harm the health of nonsmokers. It is found that exposure ... to a vast array of problems. ,In sickle ...
... show obese men with prostate cancer are at a higher ... recurrence than men of normal weight.// ,The first ... San Diego sampled nearly 3,200 prostate cancer patients. In this ... defined as having a body mass index higher than 30. ...
... valacyclovir may significantly reduce the spread of the genital ... each case, one partner was diagnosed with //type 2 ... Type 2 herpes causes a chronic genital viral infection ... herpes were given either 500 milligrams of valacyclovir once ...
... New research proves drug-coated stents effectively combat death, heart ... a closer look at the effects of drug-coated stents ... 500 patients with previously untreated blocked arteries who were ... comparable blockages were treated with bare metal stents. ...
... million service men and women before and after the Air ... rate of suicide seen among Air Force personnel. // ... for black and white males ages 24 to 35, between ... are to provide support for soldiers facing mental health or ...
... simplex virus is a common eye disease affecting people worldwide. ... cases are identified // annually. The disease is caused by ... get the infection will have repeat infections. The recurrence rate ... five years, and 67 percent within seven years. ...
Cached Medicine News:Health News:Prostate Cancer in Obese Men 2
...
Small diameter high tech flexoscopes...
... cervical plate system features an advanced design ... needs. Trinica system gives surgeons the flexibility ... unique anatomy. Flexibility is built-in to every ... and the innovative Secure-Twist anti-migration system to ...
... intended for supportive stabilization of the ... The device utilizes bi-cortical fixation for ... enhanced through dynamic screw holes and ... level interbody fusion. Anterior cervical corpectomy. ...
Medicine Products: